Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

10 May 2016 - 16 May 2016
11 May 2016 - 13 May 2016

Diabetes Drug Decreases Psychostimulant Addiction Behavior

By BiotechDaily International staff writers
Posted on 06 Nov 2012
Print article
Researchers report a drug currently used for the medical management of type 2 diabetes could also be effective for treating addiction to often-abused psychostimulants.

Researchers from Vanderbilt University (Nashville, TN, USA) have found that a brain mechanism known to be a therapeutic target in treating type 2 diabetes mellitus also appears to be involved in some forms of drug addiction. In a study of cocaine addiction, animals were injected with the diabetes drug Exendin-4, a longer-lasting analog of the natural hormone glucagon-like peptide-1 (GLP-1), which is released in response to nutrient ingestion and is a regulator of energy metabolism and feeding behavior. The resulting behavior showed significant reduction of the rewarding effects of cocaine and the findings were consistent over a broad range of Exendin-4 dosage. The study reported no evidence of negative side effects or addiction to Exendin-4 treatment.

“We suspect that this is a general mechanism that will translate to additional drugs of abuse, especially other stimulants, like amphetamine and methamphetamine,” said Gregg Stanwood, PhD, assistant professor of Pharmacology and an investigator in the Vanderbilt Kennedy Center and Vanderbilt Brain Institute. "I think the power of this research is that it is so easily translatable to humans because [Extendin-4] is already FDA approved [for diabetes]," said Aurelio Galli, PhD, professor of Molecular Physiology and Biophysics, Vanderbilt Brain Institute investigator, and codirector of the Neuroscience Program in Substance Abuse. "Any disease that is based on dysregulated dopamine can be potentially targeted. There is a lot of comorbidity between metabolic disorders like diabetes and obesity and psychiatric disease like addiction and schizophrenia."

Prof. Stanwood noted that although it is important to be very cautious in extrapolating the results to humans, these are encouraging data. “There are no medically based therapies for stimulant addiction that have been successful in the clinic, although there are a variety of psychosocial and behavioral therapies that are somewhat effective in some people,” said Prof. Stanwood. “The beauty of this is that it targets a completely new mechanism so we are cautiously hopeful [...]. We don’t expect this to be a magic bullet where one can simply take this drug and their addiction goes away, but hopefully a medicine like this, in combination with social and behavioral support, will help an addict on the road to recovery.”

The findings were published early online October 23, 2012, in the journal Molecular Psychiatry.

Related Links:

Vanderbilt University



Print article

Channels

Genomics/Proteomics

view channel
Image: An artistic rendering of the Zika virus structure (Photo courtesy of Dr. Guntur Fibriansah, Duke-NUS Medical School).

High Resolution Structure of Zika virus Expected to Aid Vaccine Development

A team of molecular virologists used advanced cryo-electron microscopy techniques to establish a high-resolution structure for the Zika virus, a formerly neglected pathogen that has recently been associated... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.